Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioNTech SE
In the first of a three-part series on the evolution of mRNA manufacturing, this article looks back to before the pandemic, when dogged mRNA researchers and entrepreneurs labored in obscurity pursuing the dream of revolutionizing health care by commandeering the body’s own protein building process to generate quicker, cheaper vaccines and therapeutics. Then the mRNA COVID-19 vaccines stunned the world.
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
US Bivalent COVID Booster Purchases Would Cover About Half Of Population At More than 50% Price Hike
The government is paying a premium for updated vaccines despite the much smaller data packages that will be available at the time of a potential authorization and rollout. The administration also currently lacks funding for boosters for all, but demand may not necessitate such a supply.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- BioNTech US Inc.
- Biopharmaceutical New Technologies AG
- Neon Therapeutics, Inc.
- BioNTech AG